Company Filing History:
Years Active: 2020
Title: Maher M Aljohani: Innovator in Anti-Coagulant Sensing Technologies
Introduction
Maher M Aljohani is a prominent inventor based in Riyadh, Saudi Arabia. He has made significant contributions to the field of biomedical sensing technologies, particularly in the development of DNA aptamers for therapeutic drug monitoring.
Latest Patents
Aljohani holds a patent for "Full-length and truncated anti-coagulant Dabigatran etexilate specific DNA aptamers for electrochemical and fluorescence sensing applications." This innovative work focuses on creating long and short aptamer sequences that serve as high-affinity and specificity tools for analyzing the drug Dabigatran etexilate. The aptamers are designed for therapeutic drug monitoring, pharmacokinetic studies, and naturalization studies. Through a series of selection and enrichment rounds using a randomized 60-mer DNA library, specific aptamer sequences were successfully identified. The binding affinity and specificity of these aptamers were evaluated, showing dissociation constants ranging from 47-312 nM with minimal cross-reactivity to other analytes. The use of fluorophore and quencher-labeled complementary sequences allowed for mapping the binding region within the aptamer by monitoring fluorescence signal changes. A truncated sequence was utilized to construct a turn-on fluorescence sensor, demonstrating the potential clinical applications of these aptamers in diagnostics.
Career Highlights
Maher M Aljohani is affiliated with Alfaisal University, where he continues to advance research in the field of biosensors and drug monitoring technologies. His work has garnered attention for its innovative approach and potential impact on clinical diagnostics.
Collaborations
Aljohani has collaborated with notable colleagues, including Raja Chinnappan and Mohammed Zourob, contributing to the advancement of research in his field.
Conclusion
Maher M Aljohani's contributions to the development of DNA aptamers for drug monitoring highlight his innovative spirit and dedication to improving clinical diagnostics. His work promises to have a significant impact on the future of therapeutic drug analysis.